Home > Insider Trading > Filing (0001127602-21-000541)

Filing Details

Accession Number:: 0001127602-21-000541
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-05 16:24:20
Reporting Period:: 2021-01-04

Accepted Time:: 2021-01-05 16:24:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	Biological Products, (No Disgnostic Substances) (2836)	813467528

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1690927	Zvi Tal Zaks	C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-04	5,000	$12.21	5,000	No	4	M	Direct
Common Stock	Disposition	2021-01-04	100	$103.51	4,900	No	4	S	Direct
Common Stock	Disposition	2021-01-04	600	$105.07	4,300	No	4	S	Direct
Common Stock	Disposition	2021-01-04	445	$106.52	3,855	No	4	S	Direct
Common Stock	Disposition	2021-01-04	400	$108.02	3,455	No	4	S	Direct
Common Stock	Disposition	2021-01-04	1,802	$110.09	1,653	No	4	S	Direct
Common Stock	Disposition	2021-01-04	1,253	$111.14	400	No	4	S	Direct
Common Stock	Disposition	2021-01-04	300	$112.29	100	No	4	S	Direct
Common Stock	Disposition	2021-01-04	100	$112.96	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-01-04	5,000	$0.00	5,000	$12.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
189,952		2027-10-03	No	4	M	Direct

Footnotes

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.78 to $105.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.90 to $106.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.74 to $108.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.69 to $110.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.73 to $111.60 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.74 to $112.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).